Adaptive Biotechnologies signed two non‑exclusive agreements with Pfizer to license its T‑cell receptor discovery platform and large TCR‑antigen mapping datasets for rheumatoid arthritis and broader AI training. Adaptive will receive upfront payments and is eligible for milestone and commercial payments that could total up to roughly $890 million. The deals aim to accelerate target discovery and AI model training across immunology programs.